Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H12N2 |
Molecular Weight | 136.1943 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCCC1=CC=CC=N1
InChI
InChIKey=UUQMNUMQCIQDMZ-UHFFFAOYSA-N
InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2990946Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11700150 | https://www.ncbi.nlm.nih.gov/pubmed/18447604 | https://www.ncbi.nlm.nih.gov/pubmed/19300572
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2990946
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11700150 | https://www.ncbi.nlm.nih.gov/pubmed/18447604 | https://www.ncbi.nlm.nih.gov/pubmed/19300572
Betahistine is an orally administered, centrally acting histamine H1 receptor agonist with partial H3 antagonistic activity. It is proposed that betahistine may reduce peripherally the asymmetric functioning of the sensory vestibular organs in addition to increasing vestibulocochlear blood flow by antagonising local H3 heteroreceptors. Betahistine acts centrally by enhancing histamine synthesis within tuberomammillary nuclei of the posterior hypothalamus and histamine release within vestibular nuclei through antagonism of H3 autoreceptors. This mechanism, together with less specific effects of betahistine on alertness regulation through cerebral H1 receptors, should promote and facilitate central vestibular compensation. Betahistine is used to treat the symptoms associated with Ménière's disease, a condition of the inner ear which causes, vertigo (dizziness), tinnitus (ringing in the ears), hearing loss.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5076 |
31.0 µM [Ki] | ||
Target ID: CHEMBL4124 |
6.9 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Betahistine Approved UseBetahistine is used to treat the symptoms associated with Ménière's disease, a condition of the inner ear which causes, vertigo (dizziness), tinnitus (ringing in the ears), hearing loss. Launch Date-5.14944E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
339.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14765546/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
2-PYRIDINEACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1196 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14765546/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
2-PYRIDINEACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14765546/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
2-PYRIDINEACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
72 mg 3 times / day multiple, oral Highest studied dose Dose: 72 mg, 3 times / day Route: oral Route: multiple Dose: 72 mg, 3 times / day Sources: |
healthy, 20-31 n = 12 Health Status: healthy Age Group: 20-31 Sex: M+F Population Size: 12 Sources: |
|
728 mg 1 times / day single, oral Overdose Dose: 728 mg, 1 times / day Route: oral Route: single Dose: 728 mg, 1 times / day Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Histamine receptor type coupled to nitric oxide-induced relaxation of guinea-pig nasal mucosa. | 2002 Oct-Dec |
|
Alternobaric oxygen therapy in long-term treatment of Ménière's disease. | 2002 Winter |
|
[Current approaches to the treatment of vertigo in children]. | 2003 |
|
Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea. | 2003 |
|
Menière's disease. | 2003 Jun |
|
Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. | 2003 Jun |
|
[Cerebral hemodynamics and statokinetic functions in patients with vertebral basilar vascular insufficiency]. | 2004 |
|
Betahistine in vertebrobasilar insufficiency. | 2004 |
|
Investigation of Betaserc in auditory and vestibular disturbances. | 2004 |
|
Management of idiopathic sudden sensorineural hearing loss: experience in newly developing Qatar. | 2004 |
|
[Betaserc treatment of psychogenic vertigo]. | 2004 |
|
[Rehabilitation of patients with peripheral vestibular disorders]. | 2004 |
|
Meniere's disease. | 2004 Dec |
|
Acute and clinically relevant drug-induced liver injury: a population based case-control study. | 2004 Jul |
|
Menière's disease. | 2004 Jun |
|
Usefulness of high doses of glucocorticoids and hyperbaric oxygen therapy in sudden sensorineural hearing loss treatment. | 2004 Nov |
|
Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo : A Double-Blind, Randomised Clinical Study. | 2005 |
|
[Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke]. | 2005 |
|
[Efficacy of betaserk in experimental motor disease]. | 2005 |
|
[Betaserk in the treatment of aftereffects of craniocerebral injury and vascular events]. | 2005 |
|
[Betaserc and improvement of life quality in war veterans]. | 2005 |
|
Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. | 2005 |
|
Benign paroxysmal positional vertigo: a study of two manoeuvres with and without betahistine. | 2005 Apr |
|
Menière's disease. | 2005 Dec |
|
Histamine (H3) receptors modulate the excitatory amino acid receptor response of the vestibular afferents. | 2005 Dec 7 |
|
A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. | 2005 Feb |
|
Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. | 2005 Jul |
|
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. | 2005 Mar |
|
Effects of betahistine on the spatiotemporal response properties of vestibulospinal neurons to labyrinthine volleys. | 2005 May 16 |
|
[Vertigo attacks -- current therapy]. | 2005 Nov |
|
Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro. | 2005 Nov |
|
West Nile virus infection and conjunctival exposure. | 2005 Oct |
|
[Assessment of betahistine dihydrochloride effectiveness in the treatment of disturbance of balance system, based on analysis of doctors and patients questionnaires results]. | 2006 |
|
[Clinical effectiveness of betahistine in monotherapy of vertigo for different etiology]. | 2006 |
|
[Betaserc in the treatment of vestibular dysfunctions of different etiology]. | 2006 |
|
[Efficacy of Betahistine Mesilate combined with Flunarizine Hydrochloride for treating tinnitus]. | 2006 Apr |
|
Betahistine in the treatment of vertiginous syndromes: a meta-analysis. | 2006 Aug |
|
Pharmacological advances in the treatment of neuro-otological and eye movement disorders. | 2006 Feb |
|
[Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystagmography test results]. | 2006 Mar |
|
Role of H1 receptors in histamine-mediated up-regulation of STAT4 phosphorylation. | 2006 Mar |
|
Restoration of vestibular function: basic aspects and practical advances for rehabilitation. | 2006 Sep |
|
Role of apolipoprotein E in anxiety. | 2007 |
|
'Complementary ENT': a systematic review of commonly used supplements. | 2007 Aug |
|
Optimizing the pharmacological component of integrated balance therapy. | 2007 Jan-Feb |
|
Histaminergic ligands improve vestibular compensation in the cat: behavioural, neurochemical and molecular evidence. | 2007 Jul 30 |
|
Histamine affects STAT6 phosphorylation via its effects on IL-4 secretion: role of H1 receptors in the regulation of IL-4 production. | 2007 Mar |
|
Reversible sensorineural hearing loss in a girl with Kawasaki disease. | 2007 Oct-Dec |
|
A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study. | 2008 |
|
Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation. | 2008 Jan |
|
Case report: a case of intractable Meniere's disease treated with autogenic training. | 2008 Jan 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/product/4160/smpc
The usual dose is one tablet (16mg) or two tablets (8mg) three times a day, preferably taken with meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7688057
Treatment with dimaprit at 6 and 60 uM for 20 min significantly inhibited the anaphylactic histamine release, whereas betahistine at up to 80 uM under the same conditions did not affect it.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN07CA01
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
||
|
WHO-ATC |
N07CA01
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BETAHISTINE
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
1502
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
346
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
CHEMBL24441
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
100000085867
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
DTXSID3022665
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
D001621
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
227-086-4
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
5638-76-6
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
1511
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB05794MIG
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
DB06698
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
35677
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
X32KK4201D
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
m2450
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | Merck Index | ||
|
2366
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
C83554
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY | |||
|
42617
Created by
admin on Fri Dec 15 15:10:36 UTC 2023 , Edited by admin on Fri Dec 15 15:10:36 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)